Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

This study is to assess the efficacy and safety of agents targeting DNA damage repair with olaparib versus olaparib monotherapy in second or third line setting in patients with triple-negative breast cancer prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the homologous recombination repair pathway. Treatment arms are olaparib monotherapy, olaparib+AZD6738 and olaparib+AZD1775.

Patient Profile

Triple Negative Breast Cancer with evidence of metastatic disease.

Where’s this trial being run?

Cork University Hospital, St Vincents University Hospital, and University Hospital Galway

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: VIOLETTE
Number: 17-33 (D5336C 00001)
Full Title:

A Phase II, Open Label, Randomised, Multi-centre Study to assess the safety and efficacy of agents targeting DNA damage repair in combination with Olaparib versus Olaparib Monotherapy in the treatment of metastatic triple negative breast cancer patients stratified by alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2).

Principal Investigator: Prof John Crown (St Vincent's University Hospital)
Type: Industry Sponsored
Sponsor:

AstraZeneca

Recruitment Started: Global: 2018
Ireland: 2018
Global Recruitment Target: 450
Ireland Recruitment Target: 12